Identification of XXXX -associated-antigens via screening of recombinant proteins from the @entity1 expression cDNA library (SEREX).

@entity1 @entity64 @entity301 @entity2998 @entity32686 @entity385
BACKGROUND: Because circulating antibodies against a variety of antigens have been detected in @entity1 with @entity301 , @entity2998 and those who have suffered a @entity64 , it is suspected that immune response may be one of the mechanisms of atherogenesis The objective of this study is to identify novel antibodies in @entity385 @entity1 by screening the expressed recombinant proteins using a @entity1 cDNA library (SEREX). METHODS: To identify the candidate antigens, cDNA library was screened by SEREX using plasma from ten @entity1 with @entity385 . Subsequently, via ELISA using recombinant proteins and synthetic peptides, the serum antibody levels were measured in two independent @entity1 /healthy donor (HD) cohorts (142 and 78 in the 2nd screening and a validation cohort, respectively). RESULTS: The initial screening resulted in the identification of six candidate antigens. Of these antigens, @entity32686 ( @entity32686 ) was determined to be the antigen associated with @entity64 (P   <   0.05) by ELISA with 2nd screening and validation cohort. Multifactorial logistic regression analysis showed that the increased levels of the @entity32686 antibodies ( @entity32686 -Abs) associated with @entity64 independent of other risk factors for @entity64 (P   <   0.05). Receiver operating curve analysis demonstrated that the area under the curve from ELISA using GST fusion @entity32686 and synthetic peptides (bRPA2-132) were 0.867 (95% CI: 0.798-0.936) and 0.971 (95% CI: 0.940-1.00), respectively. If the cut-off value of the bRPA2-132-Ab level was determined to be 0.334, the sensitivity and specificity of the antibody level as the diagnostic marker for @entity64 were 0.323 (95% CI: 0.209-0.453) and 1.00 (95% CI: 0.713-1.00), respectively. CONCLUSIONS: SEREX identified @entity32686 as the antigen associated with @entity385 and serum auto-antibodies against @entity32686 elevates in @entity64 @entity1 . @entity32686 -Abs could become a biomarker for the evaluation of @entity385 at risk.
